Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy
Open Access
- 7 December 2011
- journal article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 9 (1), 209
- https://doi.org/10.1186/1479-5876-9-209
Abstract
Breast cancer stem cells (BCSCs) are the source of breast tumors. Compared with other cancer cells, cancer stem cells show high resistance to both chemotherapy and radiotherapy. Targeting of BCSCs is thus a potentially promising and effective strategy for breast cancer treatment. Differentiation therapy represents one type of cancer stem-cell-targeting therapy, aimed at attacking the stemness of cancer stem cells, thus reducing their chemo- and radioresistance. In a previous study, we showed that down-regulation of CD44 sensitized BCSCs to the anti-tumor agent doxorubicin. This study aimed to determine if CD44 knockdown caused BCSCs to differentiate into breast cancer non-stem cells (non-BCSCs).This publication has 63 references indexed in Scilit:
- Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthaseBreast Cancer Research and Treatment, 2010
- MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transitionOncogene, 2010
- Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesisOncogene, 2010
- Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virusHuman Pathology, 2009
- HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasionOncogene, 2008
- Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenograftsProceedings of the National Academy of Sciences of the United States of America, 2008
- WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonistsSeminars in Oncology, 2003
- Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2003